Inicio Área de profesionales Artículos publicados Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Correo electrónico Imprimir

M. Martin, A. Lluch, A. Ruiz, M. Ramos, E. Adrover, A. Rodríguez-Lescure, R. Grosse, L. Calvo, C. Fernández-Chacón, M. Roset, A. Antón, D. Isla, P. Martínez del Prado, L. Iglesias, J. Zaluski, A. Arcusa, J. M. López-Vega, M. Muñoz and J. R. Mel. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology 2006; 17(8):1205-1212.

Para más información vaya al siguiente enlace:

http://annonc.oxfordjournals.org/content/17/8/1205.abstract